Contrasted performances for METEX in the first quarter of 2024

The METabolic EXplorer group announces a mixed evolution of its turnover for the first quarter of 2024, with a notable increase in the field of specialties but a significant decrease for commodities.

Specialty sales reached €23.3 million, up 17% compared to the same period the previous year, driven by products such as Tryptophan and Valine. However, this increase is not enough to offset the decline in sales of commodities such as Lysine, affected by intense competition and high production costs. The latter fell by 45%, reaching 6.8 million euros.

The group's total turnover thus stands at 30.0 million euros, marking a reduction of 7% compared to the first quarter of 2023. The share of specialties in overall turnover has however increased, from 62% to 77%.

In this difficult context, METEX seeks to mobilize public authorities to restore more balanced competition on European markets. However, the company also had to request an extension of the deadline for holding its annual general meeting due to an inability to finalize its accounts for the 2023 financial year.